Market Place
Sourcing Support
Royalty Pharma nabs $475M milestone from Pfizer upon migraine nasal spray OK
17 Mar 2023 //
ENDPTS
US FDA approves Pfizer`s nasal spray for migraine
11 Mar 2023 //
REUTERS
US Neurologists Cautiously Optimistic About Approval of Pfizer`s Zavegepant
28 Feb 2023 //
PR NEWSWIRE
Pfizer Announces The Lancet Neurology Has Published PIII Data for Zavegepant
16 Feb 2023 //
BUSINESSWIRE
US FDA Accepts for Review Biohaven`s NDA Filing of Intranasal Zavegepant
23 May 2022 //
PRNEWSWIRE
Welcome to new (Bio) Haven: CEO hopes to strike gold twice
11 May 2022 //
FIERCEBIOTECH
Biohaven`s intranasal migraine therapy hits main goals of Phase III study
07 Dec 2021 //
NASDAQ
Biohaven and Pfizer partner to market migraine drugs outside the US
10 Nov 2021 //
PHARMACEUTICAL-TECHNOLOGY
Biohaven Receives FDA May Proceed Letter to Begin Ph2 Trial Vazegepant
08 Apr 2020 //
PRNEWSWIRE
Biohaven begins phase 2/3 trial of BHV-3500 for acute treatment of migraine
02 Apr 2019 //
PHARMABIZ
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.